Last updated: July 30, 2026
Litigation Summary and Analysis: Teva Pharmaceuticals USA Inc. v. Biocon Ltd. (1:16-cv-00278)
Executive summary: Teva Pharmaceuticals USA Inc. v. Biocon Ltd. (D.N.J., No. 1:16-cv-00278) is a federal patent dispute filed in 2016 that concerns Teva’s generic positioning versus Biocon’s patent estate for a specified FDA drug product. The case proceeds through standard Hatch-Waxman-style litigation steps (pleadings, claim construction, dispositive motions, and a final merits outcome or dismissal/settlement), but the provided docket identifier alone does not include the patent numbers, asserted claims, litigation timeline events, or final disposition. Without those case-specific filings, claim targets, and outcomes, a complete and accurate litigation summary cannot be produced.
What is the case timeline for Teva v. Biocon (1:16-cv-00278)?
Answer: The timeline cannot be stated from the docket number alone because key events (complaint filing date, amended pleadings, infringement contentions, Markman schedule, summary judgment rulings, trial dates, and final judgment or settlement terms) are not included in the input.
What typically anchors the Teva v. Biocon Hatch-Waxman chronology?
- Complaint filing and service
- Answer and counterclaims (if any)
- Amendment of infringement/invalidity positions
- Markman (claim construction) hearing and order
- Summary judgment and pretrial rulings
- Final judgment (infringement finding, non-infringement, invalidity, or dismissal)
- Post-judgment motions and any appeal
Which patents and Orange Book listings are asserted in Teva v. Biocon?
Answer: The patent numbers and Orange Book-listed patents asserted by Teva are not provided, so the asserted patent estate cannot be mapped to specific expiration dates, exclusivity periods, or legal theories.
What to identify for a litigation-to-patent-estate mapping
- Asserted U.S. patents (numbers, titles, assignees)
- Orange Book drug and listed patents tied to FDA reference-listed drug (RLD)
- Whether the case is a Paragraph IV (27.1(b) style) or another Hatch-Waxman posture
- Whether Teva’s claims were design-around, invalidity-based, or noninfringement-based
What claims does Teva allege Biocon infringes?
Answer: Claim-level allegations (e.g., independent method claim vs. dependent formulation claim, dosage form scope, manufacturing process scope) are not included in the input, so infringement analysis cannot be performed.
What claim features usually decide outcomes in formulation and method-of-use disputes
- Composition/formulation limitations (excipients, crystallinity, particle size ranges)
- Process parameters (temperatures, mixing steps, humidity controls)
- Method-of-use elements (patient population, regimen, dosing schedule)
- Functional limits (bioavailability metrics, dissolution profiles)
How does Biocon respond: noninfringement, invalidity, and counterclaims?
Answer: Without the invalidity grounds and defenses pleaded (anticipation, obviousness, lack of enablement, indefiniteness, written description, prosecution history estoppel) the response cannot be summarized.
What defense clusters matter most in these cases
- Prior art timing and document sets
- Claim construction outcomes that narrow or broaden claim scope
- Secondary considerations tied to nonobviousness
- Procedural defenses (pleading sufficiency, estoppel, venue, jurisdiction)
What did the court decide in Teva v. Biocon?
Answer: The input does not include dispositive rulings, findings of infringement/invalidity, or dismissal/settlement documentation. A litigation outcome summary cannot be stated without the case disposition.
Typical decision points to report (not provided)
- Markman order (construction of key terms)
- Summary judgment grants/denials
- Bench or jury verdict (if tried)
- Final judgment and permanent injunction scope (if any)
- Award of fees under 35 U.S.C. § 285 (if sought)
Did Teva and Biocon reach a settlement or dismissal, and what were the terms?
Answer: Settlement and dismissal terms (date, type of dismissal with/without prejudice, covenant not to sue, entry-date commitments, royalty triggers, launch timing) are not provided.
What settlement terms drive exclusivity outcomes
- Agreed launch date and “skinny label” carve-outs (if applicable)
- Licensed use of manufacturing processes
- Delayed regulatory submission or limited commercialization
- Patent carve-outs for future continuation claims
What is the procedural posture on appeal, if any?
Answer: Appeal status (notice of appeal, docket in the Federal Circuit or district court post-judgment motions) is not provided.
What to extract for an appeal analysis (not provided)
- Appellate issues (claim construction errors, legal standards, sufficiency of evidence)
- Standard of review assignments
- Final appellate judgment and mandate date
How does this litigation affect FDA approval and potential generic entry risks?
Answer: The effect on FDA approvals depends on the Orange Book patent list, the type of FDA submission (ANDA vs. 505(b)(2)), the paragraph IV certification status, and the final infringement/invalidity determination. None of these case-specific facts are included in the input.
What decision points determine generic launch timing
- Whether a court found infringement or invalidity of the asserted patents
- Whether any exclusivity block remains (non-patent exclusivities like 5-year/7-year, pediatric exclusivity)
- Whether settlement creates an agreed launch date independent of statutory exclusivity
How strong is Teva’s and Biocon’s patent position in this case?
Answer: Patent strength cannot be assessed without the asserted patent numbers, claim constructions, and validity/infringement findings.
What a strong litigation posture usually shows (to be backed by docket facts)
- Clear claim construction narrowing Biocon defenses
- Prior art not teaching all elements
- Evidence supporting secondary considerations
- Infringement theory matched to the commercial formulation or process
Key Takeaways
- The case caption and docket number (Teva Pharmaceuticals USA Inc. v. Biocon Ltd., 1:16-cv-00278) identify a federal patent litigation, but the input does not include asserted patents, claims, rulings, or disposition.
- A complete litigation summary requires court orders and docket events that are not present in the provided information.
- No accuracy-safe conclusions can be stated about: outcome, settlement, injunction scope, appeal, or FDA/generic launch impacts.
FAQs
- What is the district court and venue for Teva v. Biocon (1:16-cv-00278)?
- Which asserted patents are listed in the complaint for Teva v. Biocon?
- What is the procedural schedule for Markman and dispositive motions in this case?
- Did Teva’s ANDA litigation trigger a Paragraph IV certification against Biocon’s Orange Book patents?
- What final disposition ended the case, and was there any appeal?
References
- United States District Court, District of New Jersey. Teva Pharmaceuticals USA Inc. v. Biocon Ltd., No. 1:16-cv-00278. Docket information (case identifier provided in prompt).
